US Agrees To Pay Pfizer Nearly $2B For Additional 3.7M Courses Of COVID-19 Antiviral Nirmatrelvir/Ritonavir

Reuters (12/13, Erman) reports, “The U.S. government agreed to pay Pfizer Inc nearly $2 billion for an additional 3.7 million courses of its COVID-19 antiviral treatment” nirmatrelvir/ritonavir (Paxlovid), “the company said on Tuesday.” This “new purchase...